Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Knight Therapeutics Inc (GUD.TO)

Knight Therapeutics Inc (GUD.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 580,969
  • Shares Outstanding, K 101,214
  • Annual Sales, $ 328,199 K
  • Annual Income, $ -16,835 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.34
  • Price/Sales 1.75
  • Price/Cash Flow 9.41
  • Price/Book 0.76
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.20
  • Most Recent Earnings $-0.02 on 08/08/24
  • Next Earnings Date 11/07/24 [BMO]
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Drug Specialty & Generic

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.02
  • Number of Estimates 2
  • High Estimate 0.06
  • Low Estimate -0.02
  • Prior Year 0.09
  • Growth Rate Est. (year over year) -77.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.13 +3.51%
on 11/07/24
5.98 -11.20%
on 10/08/24
-0.67 (-11.20%)
since 10/07/24
3-Month
5.13 +3.51%
on 11/07/24
6.23 -14.77%
on 09/17/24
-0.23 (-4.15%)
since 08/07/24
52-Week
4.70 +12.98%
on 11/08/23
6.23 -14.77%
on 09/17/24
+0.52 (+10.86%)
since 11/07/23

Most Recent Stories

More News
Stocks in play: Knight Therapeutics Inc.

Today reported financial results for its third quarter ended September 30, 2024. The company delivered ...

GUD.TO : 5.29 (-7.84%)
Knight Therapeutics Reports Third Quarter 2024

GUD.TO : 5.29 (-7.84%)
Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call

GUD.TO : 5.29 (-7.84%)
Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

GUD.TO : 5.29 (-7.84%)
INCY : 81.37 (+0.52%)
Stocks in play: Knight Therapeutics Inc.

Will release its fourth-quarter and year-end 2023 financial results on Thursday, March 21, prior to ...

GUD.TO : 5.29 (-7.84%)
Stocks in play: Knight Therapeutics Inc.,

Announced today the launch of Minjuvi® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. ...

GUD.TO : 5.29 (-7.84%)
Stocks in play: Knight Therapeutics Inc.

Has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc., a biopharmaceutical ...

GUD.TO : 5.29 (-7.84%)
Stocks in play: Knight Therapeutics Inc.

Reported financial results for its third quarter ended September 30, 2023. All currency amounts are ...

GUD.TO : 5.29 (-7.84%)
Stocks in play: Knight Therapeutics Inc.

Has received pricing approval for Minjuvi® (tafasitamab) from the Drugs Market Regulation Chamber (“CMED”). ...

GUD.TO : 5.29 (-7.84%)
Stocks in play: Knight Therapeutics Inc.

Reported financial results for its second quarter ended June 30, 2023. Revenues were $89.905 million, ...

GUD.TO : 5.29 (-7.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin...

See More

Key Turning Points

3rd Resistance Point 5.94
2nd Resistance Point 5.88
1st Resistance Point 5.81
Last Price 5.29
1st Support Level 5.68
2nd Support Level 5.62
3rd Support Level 5.55

See More

52-Week High 6.23
Fibonacci 61.8% 5.65
Fibonacci 50% 5.47
Last Price 5.29
Fibonacci 38.2% 5.28
52-Week Low 4.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar